Gyre Therapeutics Inc (GYRE)
8.90
+5.93%
Gyre Therapeutics Inc (GYRE) is currently trading at $8.90. This represents a gain of 5.93% from the previous session. With a market capitalization of $0.80B, GYRE is a key component of the Health Care sector. Investors looking to trade GYRE should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Get 15 Free Stocks on Moomoo →
T&Cs Apply. Trade GYRE commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Gyre Therapeutics Inc (GYRE) shows a bullish trend. Analysts are watching the 8.90 level closely.
Fundamentals
Mkt Cap0.80B
P/E Ratio137.7200
Volume8,740
60-Day Technical Chart
Advanced Charting
Need more indicators for GYRE? Use the world's #1 platform.
Open GYRE on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $9
| Metric |
GYRE +5.93% |
MARA +4.53% |
SOUN +4.13% |
LUMN +7.52% |
|---|---|---|---|---|
| Price | $8.90 | $8.41 | $8.70 | $8.01 |
| Mkt Cap | $0.80B | $3.12B | $3.67B | $8.19B |
| - | View → | View → | View → |
Latest Headlines
Gyre Therapeutics stock soars after positive pre-NDA meeting in China
Investing.com • Jan 5, 2026
Experimental liver fibrosis drug in China moves closer to patient use
Stock Titan • Jan 5, 2026
Solid Earnings May Not Tell The Whole Story For Gyre Therapeutics (NASDAQ:GYRE)
simplywall.st • Aug 22, 2025
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
GlobeNewswire • Oct 15, 2025
Gyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis Trials
Yahoo Finance • May 29, 2025
● Gemini Agentic AI Analyst Insight for GYRE
Market Education
- Trump’s New Tariffs Could Push Up Kitchen Renovation Costs Sep 26, 2025
- Understanding Hedge Fund Alpha and Beta: A Guide for New Investors Jun 2, 2024
- Stock Valuation Dec 16, 2023
External Research